Genomma Lab Internacional SAB de CV (GEKA) Financial Statements
Genomma Lab Internacional SAB de CV Financial Overview
Genomma Lab Internacional SAB de CV's market cap is currently $719.20M. The company's EPS TTM is $1.72; its P/E ratio is 8.82; and it has a dividend yield of 5.50%. Genomma Lab Internacional SAB de CV is estimated to report earnings on February 24, 2027, and the estimated EPS forecast is $0.02. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 17.54B | $ 18.61B | $ 16.47B | $ 16.82B | $ 15.49B |
| Gross Profit | $ 11.02B | $ 11.93B | $ 10.08B | $ 10.16B | $ 9.56B |
| Operating Income | $ 3.76B | $ 3.92B | $ 3.26B | $ 3.25B | $ 3.05B |
| EBITDA | $ 3.61B | $ 4.14B | $ 2.78B | $ 3.01B | $ 2.84B |
| Net Income | $ 1.61B | $ 1.49B | $ 1.08B | $ 1.39B | $ 1.31B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 3.05B | $ 2.37B | $ 1.66B | $ 1.50B | $ 1.22B |
| Total Assets | $ 23.83B | $ 23.02B | $ 20.74B | $ 21.61B | $ 21.54B |
| Total Debt | $ 7.63B | $ 6.49B | $ 6.24B | $ 6.44B | $ 5.96B |
| Net Debt | $ 4.79B | $ 4.21B | $ 4.77B | $ 4.94B | $ 4.74B |
| Total Liabilities | $ 12.72B | $ 12.13B | $ 11.30B | $ 11.45B | $ 11.47B |
| Stockholders' Equity | $ 11.11B | $ 10.88B | $ 9.44B | $ 10.15B | $ 10.07B |
| Cash Flow | |||||
| Free Cash Flow | $ 2.03B | $ 2.36B | $ 2.16B | $ 2.04B | $ 1.26B |
| Operating Cash Flow | $ 2.05B | $ 3.03B | $ 2.25B | $ 2.05B | $ 1.47B |
| Investing Cash Flow | $ -752.80M | $ -731.97M | $ -302.21M | $ -282.30M | $ -765.62M |
| Financing Cash Flow | $ -475.40M | $ -1.59B | $ -1.68B | $ -1.36B | $ -1.47B |
Currency in MXN